LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Aandelen Lijst・ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

82.02 0.06

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

80.88

Max

82.81

Belangrijke statistieken
By Trading Economics
Inkomsten	18M 27M
Verkoop	16M 228M
K/W Sectorgemiddelde	50.838 77.671
EPS	2.04
Winstmarge	11.684
Werknemers	897
EBITDA	19M 61M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+35.07% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-270M 1.8B
Vorige openingsprijs	81.96
Vorige sluitingsprijs	82.02

Nieuwssentiment

By Acuity

27%

73%

87 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

70.05 / 71.85 Steun & Weerstand

ANI Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2025, 22:02 UTC

Winsten

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec 2025, 21:46 UTC

Winsten

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec 2025, 23:52 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec 2025, 23:36 UTC

Marktinformatie

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec 2025, 23:20 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec 2025, 23:15 UTC

Winsten

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec 2025, 22:59 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec 2025, 22:45 UTC

Marktinformatie

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec 2025, 22:40 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 22:06 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 22:02 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:00 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec 2025, 21:53 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

10 dec 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 21:33 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec 2025, 21:32 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec 2025, 21:25 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec 2025, 21:16 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec 2025, 21:15 UTC

Winsten

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Vergelijking

Prijswijziging

ANI Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

35.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 110.8 USD 35.07%

Hoogste 121 USD

Laagste 100 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor ANI Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan ANI Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

70.05 / 71.85Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

87 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.